Literature DB >> 10854959

Validity and coverage of estimates of relative accuracy.

H Cheng1, M Macaluso, J M Hardin.   

Abstract

PURPOSE: Studies comparing test accuracy often restrict the confirmation procedure to subjects classified as positive by either test. Relative sensitivity (RSN) and relative false-positive rate (RFP) are two estimable comparative measures of accuracy. This article evaluates the influence of sample size, disease prevalence, and test accuracy on the validity of point estimates of RSN and RFP, and on the coverage of their confidence intervals (CI).
METHODS: For each combination of sample size, disease prevalence, test accuracy, and interdependence between tests 1,000 samples were generated using computer simulations. The percent bias in the RSN and RFP estimates was measured by comparing the means of the 1,000 values computed in each simulation (log-transformed) with their theoretical values. Coverage of the estimated CI was measured by computing the proportion that actually included the theoretical values. Application of these methods was illustrated with data from a study comparing mammography and physical examination in screening for breast cancer.
RESULTS: RSN estimates were valid if the true number of diseased cases exceeded 30, and RFP estimates were valid if the number of nondiseased subjects exceeded 200. When the numbers of diseased and nondiseased subjects exceeded 150 each, the 95% CI of RSN and RFP provided adequate coverage of the parameters (95 +/- 2%).
CONCLUSION: Sample size is the most important variable for the validity and coverage of RSN and RFP estimates. For small samples, validity and coverage of RSN and RFP also depend on the accuracy of each test and on the degree of interdependence between the tests.

Entities:  

Mesh:

Year:  2000        PMID: 10854959     DOI: 10.1016/s1047-2797(00)00043-0

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  5 in total

1.  Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.

Authors:  L Guittet; V Bouvier; N Mariotte; J P Vallee; D Arsène; S Boutreux; J Tichet; G Launoy
Journal:  Gut       Date:  2006-08-04       Impact factor: 23.059

2.  A new method to address verification bias in studies of clinical screening tests: cervical cancer screening assays as an example.

Authors:  Xiaonan Xue; Mimi Y Kim; Philip E Castle; Howard D Strickler
Journal:  J Clin Epidemiol       Date:  2013-12-12       Impact factor: 6.437

3.  Relative accuracy of nucleic acid amplification tests and culture in detecting Chlamydia in asymptomatic men.

Authors:  H Cheng; M Macaluso; S H Vermund; E W Hook
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

4.  A general latent class model for performance evaluation of diagnostic tests in the absence of a gold standard: an application to Chagas disease.

Authors:  Gilberto de Araujo Pereira; Francisco Louzada; Valdirene de Fátima Barbosa; Márcia Maria Ferreira-Silva; Helio Moraes-Souza
Journal:  Comput Math Methods Med       Date:  2012-07-31       Impact factor: 2.238

5.  Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location.

Authors:  L Guittet; V Bouvier; N Mariotte; J P Vallee; R Levillain; J Tichet; G Launoy
Journal:  Br J Cancer       Date:  2009-03-31       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.